Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.
ARCO National Construction, an industry-leading design-build general contractor, proudly announces the establishment of ARCO Life Science & Advanced Manufacturing, a division of ARCO National ...
The agency gave Akebia’s drug an OK after receiving more safety data, but imposed a strict boxed warning for its use that may limit uptake.
An arm of the private equity firm pledged up to $750 million in funding for Moderna’s flu shot development, in exchange for milestones and royalties.
Boundless is something of an outlier among the biotechs that have recently gone public. More than half of the drug companies that have priced IPOs since January 2023 have had drugs in Phase 2 testing ...